130 related articles for article (PubMed ID: 36470820)
21. Blood thyroglobulin and TSH receptor mRNA detection by RT-PCR in the follow-up of differentiated thyroid cancer patients.
Torosian L; Manrique G; Alvarez B; Lago G; Roca R; Belzarena C
Rev Esp Med Nucl; 2010; 29(3):109-13. PubMed ID: 20399540
[TBL] [Abstract][Full Text] [Related]
22. The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma.
Moon JH; Kim KM; Oh TJ; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
J Clin Endocrinol Metab; 2017 Jan; 102(1):78-85. PubMed ID: 27754806
[TBL] [Abstract][Full Text] [Related]
23. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
[TBL] [Abstract][Full Text] [Related]
24. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
25. Management of differentiated thyroid carcinomas.
Fernández-Vañes L; Llorente JL; García-Cabo P; Menéndez M; Pedregal D; Rodrigo JP; López F
Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(4):200-206. PubMed ID: 29880224
[TBL] [Abstract][Full Text] [Related]
26. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
[TBL] [Abstract][Full Text] [Related]
27. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.
Carhill AA; Litofsky DR; Ross DS; Jonklaas J; Cooper DS; Brierley JD; Ladenson PW; Ain KB; Fein HG; Haugen BR; Magner J; Skarulis MC; Steward DL; Xing M; Maxon HR; Sherman SI
J Clin Endocrinol Metab; 2015 Sep; 100(9):3270-9. PubMed ID: 26171797
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas.
Furlan JC; Bedard YC; Rosen IB
J Am Coll Surg; 2004 Mar; 198(3):341-8. PubMed ID: 14992733
[TBL] [Abstract][Full Text] [Related]
30. Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors.
Russo M; Malandrino P; Moleti M; Vermiglio F; D'Angelo A; La Rosa G; Sapuppo G; Calaciura F; Regalbuto C; Belfiore A; Vigneri R; Pellegriti G
Pediatr Blood Cancer; 2018 Sep; 65(9):e27226. PubMed ID: 29768715
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
[TBL] [Abstract][Full Text] [Related]
32. Relationship between prognostic score and thyrotropin receptor (TSH-R) in papillary thyroid carcinoma: immunohistochemical detection of TSH-R.
Tanaka K; Inoue H; Miki H; Masuda E; Kitaichi M; Komaki K; Uyama T; Monden Y
Br J Cancer; 1997; 76(5):594-9. PubMed ID: 9303357
[TBL] [Abstract][Full Text] [Related]
33. Increased incidence of thyroid cancer in Navarra (Spain). Evolution and clinical characteristics, 1986-2010.
Rojo Álvaro J; Bermejo Fraile B; Menéndez Torre E; Ardanaz E; Guevara M; Anda Apiñániz E
Endocrinol Diabetes Nutr; 2017; 64(6):303-309. PubMed ID: 28604340
[TBL] [Abstract][Full Text] [Related]
34. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro.
Hoelting T; Tezelman S; Siperstein AE; Duh QY; Clark OH
Thyroid; 1995 Feb; 5(1):35-40. PubMed ID: 7787431
[TBL] [Abstract][Full Text] [Related]
35. Initial and Dynamic Risk Stratification of Pediatric Patients With Differentiated Thyroid Cancer.
Sung TY; Jeon MJ; Lee YH; Lee YM; Kwon H; Yoon JH; Chung KW; Kim WG; Song DE; Hong SJ
J Clin Endocrinol Metab; 2017 Mar; 102(3):793-800. PubMed ID: 27809646
[TBL] [Abstract][Full Text] [Related]
36. Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes.
Balachandar S; La Quaglia M; Tuttle RM; Heller G; Ghossein RA; Sklar CA
Thyroid; 2016 Feb; 26(2):219-26. PubMed ID: 26854950
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
38. Differentiated thyroid cancer: a retrospective analysis of 832 cases from Greece.
Tzavara I; Vlassopoulou B; Alevizaki C; Koukoulis G; Tzanela M; Koumoussi P; Sotsiou F; Thalassinos N
Clin Endocrinol (Oxf); 1999 May; 50(5):643-54. PubMed ID: 10468931
[TBL] [Abstract][Full Text] [Related]
39. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
40. [Draft of the best medical treatment in patients with low-risk thyroid cancer].
Vlček P; Nováková D; Vejvalka J; Zimák J; Křenek M; Vošmiková K; Smutný S; Bavor P; Astl J; Lukáš J
Vnitr Lek; 2015 Sep; 61(9):769-77. PubMed ID: 26465275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
